Viking Therapeutics, Inc.
GB ˙ LSE ˙ US92686J1060
29,87 $ ↑0,55 (1,88%)
2026-06-04
AKTIENPREIS
SecurityGB:0VQA / Viking Therapeutics, Inc.
InstitutionProsight Management, LP
Latest Disclosed Ownership45,000 shares
Latest Disclosed Value $ 1,464,300
Prosight Management, LP ownership in 0VQA / Viking Therapeutics, Inc.

On May 15, 2026 - Prosight Management, LP filed a 13F-HR form disclosing ownership of 45,000 shares of Viking Therapeutics, Inc. (GB:0VQA) valued at $1,467,000 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 14, 2025 disclosing 0 shares of Viking Therapeutics, Inc.. The current value of the position is $1,344,150 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VIKING THERAPEUTICS COM 92686J106 45,000 45,000 1,464 0.2401
2025-02-14 2024-12-31 13F VIKING THERAPEUTICS COM 92686J106 0 -48,000 -100.00 0 -100.00
2024-11-14 2024-09-30 13F VIKING THERAPEUTICS COM 92686J106 48,000 -67,000 -58.26 3,039 -50.16 0.7478
2024-08-14 2024-06-30 13F VIKING THERAPEUTICS COM 92686J106 115,000 75,954 194.52 6,096 90.44 1.8221
2024-05-15 2024-03-31 13F VIKING THERAPEUTICS COM 92686J106 39,046 39,046 3,202 0.8907
2019-05-15 2019-03-31 13F VIKING THERAPEUTICS COM 92686J106 0 -624,000 -100.00 0 -100.00
2019-02-14 2018-12-31 13F VIKING THERAPEUTICS COM 92686J106 624,000 349,590 127.40 4,774 -0.13 2.4646
2018-11-14 2018-09-30 13F VIKING THERAPEUTICS COM 92686J106 274,410 274,410 4,780 2.6653
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.